Lütfi AKYOL, Mehmet YÜCESOY, Serkan DOĞAN, Mehmet ÇELİKBİLEK

PROTON POMPA İNHİBİTÖRLERİNİN YAN ETKİLERİ

Proton pompa inhibitörleri peptik ülser hastalığı, kronik non-steroid anti-inflamatuar ilaç kullanımı, H.Pylori enfeksiyonu ve eroziv özofajitte yaygın olarak kullanılmaktadır. Genel olarak iyi tolere edilmekle birlikte diğer tüm ilaçlarda olduğu gibi bu ilaçların da bek- lenmedik yan etkileri bildirilmiştir. Uzun süre kullanım sonrası hipergastrinemiye bağlı etkiler, hipomagnezemi, enterik mikrobial enfeksiyon riski, artmış pnömoni riski ve kemik kırığı riski bulunmaktadır. Özellikle uzun süre kullanan hastalar bu ilaçların muhtemel yan etkileri konusunda uyarılmalı ve peryodik olarak değerlendirilmelidir.

The Advers Effects of Proton Pump Inhibitors

Proton pump inhibitors are widely used in peptic ulcer disease, concomitant with non-steroid anti-inflammatory drug usage, H.Pylori infection, and erosive esophagitis. Although they are well tolerated, unexpected adverse effects can be seen as all other drugs. Effects of hypergastrinemia, hypomagnesemia, enteric microbial infection risk, increased pneumoniae risk and bone fracture risk may be seen with long term use. Patients who require long term use should be warned and controlled periodically about these likely adverse effects.

PDF

___

1. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012 Sep;36(5):405-13.
2. Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J 2012 Nov;105(11):613-8.
3. Harmark L, Van der Wiel HE, de Groot MC, Van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007; 64: 819823.
4. Lobera T, Navarro B, Del Pozo MD, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol 2009; 19: 5760.
5. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community- acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 116577.
6. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 204756.
7. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 294753.
8. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 139.
9. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012 Jul;5(4):219-32.
10. Jianu CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012 Jan;47(1):64-7.
11. Epstein M, McGrath S, Law F. Proton pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355: 1834-1836,.
12. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 2009;67: 169-172.
13. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011;27: 180-185.
14. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56: 112-116.
15. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987 Jan;28(1):96- 107.
16. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960
17. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398 acquired pneumonia: a population-based case-control study. Arch Intern Med 2007 May 14;167(9):950-5.
19. Eom CS, Jeon CY, Lim JW, et al. Use of acid- suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011 Feb 22;183(3):310-9.
20. OConnell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778- 781
21. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des 2002;8(23):2033-48
22. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14: 364-368
23. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313: 70-73
24. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 2008; 179:306-307
25. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011 Jul;106(7):1209-18
26. Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011 Sep;23(9):794-800.
18. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community- 27. Voelker R. Proton pump inhibitors linked to fracture risk. JAMA 2010 Jul 7;304(1):29.